International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

A Review on Management of Sickle Cell Anemia

Kiran Yadav[1], Renuka Sahu[1], Nisha Dewangan[1]
Rungta Institute of Pharmaceutical Sciences and Research, Bhilai[1]
Rungta Institute of Pharmaceutical Sciences and Research, Bhilai[2]

Submitted: 12-04-2024 Accepted: 22-04-2024

ABSTRACT
Misshaped red blood cells are the hallmark of sickle cell disease (SCD), a hereditary monogenic illness that also induces vaso-occlusive disease, vasculopathy, and systemic inflammation. Around 300,000 newborns worldwide are born with sickle cell disease (SCD). End-organ damage is a result of acute, chronic, and acute-on-chronic problems, all of which have a negative impact on life expectancy and quality. The only treatment now available for sickle cell disease (SCD) is hematopoietic stem cell transplantation, which is not practical for the great majority of patients. Thankfully, there is hope for this regrettable condition, which is causing an increasing amount of suffering worldwide, as new treatments are in late clinical trials and more are being developed.Sickle cell disease (SCD) is a genetic hemoglobin ailment that causes long chains of hemoglobin to form in capillary beds when oxygen levels are low. This leads to the creation of sickle-shaped red blood cells, gradual damage to several organs, and an increased risk of death. Worldwide, an estimated 300,000 babies are born with sickle cell disease (SCD). About 100,000 people with SCD reside in the United States, although the majority of SCD patients are found in sub-Saharan Africa, India, the Mediterranean region, and the Middle East.

Keywords: iron overload, hydroxyurea, hemoglobinopathy, sickle cell anemia, and sickle cell disease.

I. INTRODUCTION

Sickle cell (SC) anemia is a hereditary hemoglobin disorders involving a very specific molecular lesion, in which glutamic acid is exchanged for valine the 6th residue of the hemoglobin beta chain, which is produced S hemoglobin [1]. Sickle cell disease (SCD) consists of a group of disorders characterized by the presence of sickle hemoglobin. Although there are over 700 structure hemoglobin (Hb) types identified, only two (HBS, HBC) reach higher frequencies Africa. Common SCD syndromes in this region include homozygous HBSS disease (HBSS) commonly known as sicken cell anemia (SCA) and Hb SC disease. SCD was known in parts of Africa before the 20 century. Inhabitants of West African give disease specific names those that cause acute, traumatic episodes or death or refer to children destined to die and be reborn as their siblings [2, 3]. Sickle cell disease or sickle cell anemia (or depanocytosis) is a lifelong blood disorder characteristic of red blood cells that believe that a Unusual, hard, sickle shape. Sickling decreases resulting in flexibility of cells and exposure to different type complication the disease causes mutations in the hemoglobin gene. Life expectancy of 42 and 48 years for men and women, respectively [4]. Sickle cell anemia (SCA) is a type of abnormal blood disease commonly called sickle cell disease (SCD) or as common sickle room. In the human body, blood flows through small circular shape that carries oxygen to the organs where sickle cell shape is shaped (sickle) shaped cells as shown in fig.1. The life span of a normal blood cell is approximately 120 days. A new blood cell occurs after 120 days generated [5]. The life span of sickle cells is 10 to 20 days [6]. This cell is an inherited disorder that affects normal hemoglobin present in red color blood cell (RBCs) [5, 7]. Presence of sickle what does the cell make into hemoglobin? Sickle shaped cells that are very hard and sticky as shown in fig.2. This types of anemia can be severe pain, necrosis and serious causes complications, in some cases it can be death.



Fig.1. Normal blood and sickle cell in human body

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781



Fig.2. Normal blood flow and sickle cell blood flow in human body

HISTORY

- Gardner [8] sickle cell disease, late 1910s was discovered and was abbreviated as "SCD". It was first affected in America but the discussion about it sickle cell is introduced in Africa. Walter clement noel is a dental studying in Chicago where he suffered from episodes of pain and symptoms of anemia.
- He informed Dr. James B. Herrick (cardiologist) but the doctor was not interested in noels case and he advised Dr. Amest Irons.
- Dr. Amest Iron was noels tested and saw that the red blood cells are in "the shape of a sickle". Noel reported it reports to Hirik and he is interested because it is an unknown disease and later he published a magazine and dubbed it "sickle shaped cell".
- The disease was named "sickle cell anemia". By Vernon Mason in 1922. However, some elements of the disease has been previously recognized. A paper in southern Journal of Medical Pharmacology in 1846 an autopsy described an 'absence of a spleen' Runaway slave.
- African medical literature told this condition in the 1870s, where it was known locally known as ogbanj (babies who come and go) due to the very high infant mortality rate caused by it Event status history tracked reports back in 1670 in a Ghanian family [9, 10].

CAUSES OF SICKLE CELL

The cause is inherited (genetic). It's a change in a gene that tells the body how to make an important protein. It is called hemoglobin. To get SCD, you need two altered hemoglobin genes, one from each parent if you have only one of these genes, you will have sickle cell trait, which is very mild.



The most common types of SCD is where you have two sickle cell genes (sickle cell anemia) medical. The shorthand for this is hemoglobin SS or HbSS other types of SCD involve one sickle cell gene and another. A different types of abnormal hemoglobin genes these include: hemoglobin s/beta thalassemia : hemoglobin S/ lepore, hemoglobin SO billion.

SIGN AND SYMPTOMS

PREGNANCY IN SCD – Pregnancy in sickle cell complaint can be complicated as both prospective mama and bambino are at increased threat of adverse issues. The physiological changes of gestation like increased metabolic demand, increased blood density and hyperactive-

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

coagulability gets exacerbated in SCD cases leading to increased prevalence of complications like a vaso- occlusive extremity, acute casket pattern, osteonecrosis, hepatic necrosis, leg ulcers, and thromboembolic events. Vaso- occlusion also occurs in placenta leading to villous fibrosis, necrosis, and infarction, thereby causing disabled uteroplacental rotation, which leads to habitual fetal hypoxia and adverse fetal issues[11,12]. Early reports on the outgrowth of gestation in women with sickle cell anemia, depicted an nearly universal adverse outgrowth for mama and child, but with advancements in medical care, especially the preface of prepossession care, the outgrowth has dramatically bettered. This enhancement in fetomaternal outgrowth is inadequately reflected insub-Saharan Africa where the frequence and complications of sickle cell complaint in gestation is loftiest in the world, and a motherly mortality rate of0.38 –1.29/ 100,000 births and perinatal mortality rate of1.21 –2.50/ 100,000 births are still being reported.[13] This has been attributed to modest medical and prenatal care installations, and scarce so, or virtuality of prepossession care installations in utmost communities insub-Saharan Africa.

PREGNANCY MANAGEMENT IN SCD –

Physiological gestation changes as well as the damages caused by SCD. All these changes might affect the vital organs negatively. A scrupulous approach to manage the condition can save the mama as well as the fetus from enervating complications.[14]



Fig. Peripheral smear in case of sickle cell anemia (arrow indicates sickle-shaped cells)

1. Pre -conceptual care :-



Fig. Maternal lifestyle during preconception and gestation.

The significance of early mortal embryoni c and fetal life for latterly increased threat of metabolic disturbances is captured in the Developmental Origins of Health and Disease(DOHA) thesis[15]. motherly life previous to and during gestation is, thus, of consummate significance for the epigenetic mapping of the seed[16]. and underpins the intergenerational cycle of rotundity, insulin resistance, and associated diseases(Figure 5).

2. Ante – natal care :-

This section should be read in confluence with National Institute for Health and Clinical Excellence(NICE) clinical guideline Antenatal care. Routine care for the healthy pregnant woman.[17]

Prenatal care should be handed by a multidisciplinary platoon including an obstetrician

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

and midwife with experience of high- threat prenatal care and a hematologist with an interest in SCD.

Women with SCD should suffer medical review by the hematologists and be screened for end organ damage(if this has not been accepted pre-conceptually).

Women with SCD should aim to avoid pouring factors of sickle cell heads similar as exposure to extreme temperatures, dehumidification and overexertion.

patient vomiting can lead to dehumidification and sickle cell extremity and women should be advised to seek medical advice beforehand. The influenza vaccine should be recommended if it has not been administered in the former time.

3. INTRAPARTUM CARE :-

Timing of birth - There are no randomized controlled trials to mandate the applicable timing of delivery. Recent methodical review and meta-analysis [18,19] confirm increased prenatal mortality, particularly during the after stages of gestation, in part due to the complications of SCD. The pitfalls of abruption, unexplained birth, pre-eclampsia, peripartum cardiomyopathy and acute sickle cell extremity are increased and changeable. A prospective birth plan should be made, in discussion with the woman to include mode of delivery, place of labour, MDT, positions for labour, analgesia and fresh monitoring conditions that may be applicable. Due to the increased threat of placental insufficiency andpre-eclampsia, delivery between 38 and 40 weeks is frequently indicated to help late- gestation complications and associated adverse perinatal issues.

ADVICE :- Pregnant women with SCD who have a normally growing baby should be delivered between 38 and 40 weeks of gestation (2D).

4. POST – PARTUM CARE :-

In the postpartum period, it's pivotal to assess the degree of anemia exacerbated by blood loss during labor and delivery, and relief introduced when indicated. Hydration and oxygenation should be maintained, and early rallying encouraged. heads should be managed as fornon-pregnant women. Antithrombotic socks are also recommended. Webbing of invigorated for sickle hemoglobin is recommended. Mother should be advised regarding contraception, progestogen-containing contraceptives similar as the progesterone only lozenge, injectable contraceptives, and the levonorgestrel intrauterine system are safe and effective in SCD. Estrogen-containing contraceptives should be used as alternate- line agents. hedge styles are as safe and effective in women with SCD as in the general population.[20]

Drugs-

1. Hydroxyurea

Characterization: Antimetabolite

Instrument of Activity: Expands the development of fetal hemoglobin, lessening sickling of red platelets.

Use: To lessen the recurrence and seriousness of agony emergencies and complexities in sickle cell frailty.

Normal Brand Name: Hydrea

2. Torment Meds

Characterization: Analgesics

Types:

Over-the-counter (OTC) pain killers: e.g., ibuprofen, acetaminophen.

Solution narcotics for serious torment.

Use: Torment the board during sickle cell emergencies.

Normal Drugs:

OTC: Advil, Tylenol

Solution: Morphine, Oxycodone[21]

3. Blood Bondings

Use: To supplant harmed red platelets with sound ones in instances of serious weakness or intense complexities.

Procedure: Trade bondings might be finished to bring down the level of sickle cells in the blood.

4. Iron Chelation Treatment

Characterization: Chelating Specialists

System of Activity: Eliminates overabundance iron from the body.

Use: To oversee iron over-burden from regular blood bondings.

Normal Drugs: Deferasirox (Exjade), Deferoxamine (Desferal)[22]

5. Anti-microbials

Use: To forestall or treat bacterial diseases, as individuals with sickle cell sickliness are more powerless to contaminations.

Usually Recommended: Penicillin, Cephalexin

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

6. Vaccination
Use: Routine immunizations to lessen the gamble of contaminations in people with sickle cell weakness.
Examples: Pneumococcal antibody, Haemophilus influenzae type b (Hib) immunization.[23]

7. Bone Marrow Transplantation
Use: Thought about in serious cases, particularly in youngsters, as it might possibly fix sickle cell frailty.
Procedure: Includes supplanting the bone marrow with sound foundational microorganisms from a contributor.

8. Pneumonic Hypertension Prescriptions
Order: Different classes of medications
Use: To oversee pneumonic hypertension, an entanglement that might happen in certain people with sickle cell weakness.
Examples: Endothelin receptor adversaries, phosphodiesterase-5 inhibitors.

9. Other Strong Treatments
Use: To supplement the treatment plan and work on generally wellbeing and prosperity.
Components: Sufficient hydration, way of life changes (e.g., staying away from triggers), and agony the executives.[24]

Treatment
Pain (torment) management:
- Torment is a typical and extreme side effect of sickle cell paleness.
- Over-the-counter pain killers can assist with less than overwhelming agony.
- Serious agony frequently requires remedy narcotics.
- Hydration and warm packs can give alleviation.

Disease modifying Drugs:
- Hydroxyurea increments fetal hemoglobin creation, lessening sickling and complexities.
- It's utilized to diminish torment emergencies and seriousness.

Blood Transfusions:
- Controlled in serious frailty, intense entanglements, or to forestall stroke.
- Trade bondings bring down the level of sickle cells in the blood.[25]

Iron Chelation Treatment:
- Important to eliminate overabundance iron from successive bondings.
- Drugs like deferasirox or deferoxamine are utilized.

Infection prevention :
- Anti-infection agents (e.g., penicillin) are endorsed to forestall diseases.
- Inoculations (e.g., pneumococcal, Hib) decrease contamination risk.[26]

Respiratory Hypertension The executives:
- Some foster pneumonic hypertension, dealt with explicit meds.
- Models incorporate endothelin receptor bad guys and phosphodiesterase-5 inhibitors.

Bone Marrow Transplantation:
- Held for extreme cases, frequently in youngsters.
- Might possibly fix sickle cell weakness by supplanting bone marrow with sound undifferentiated organisms.[27]

Strong Consideration and Way of life Measures:
- Satisfactory hydration forestalls emergencies.
- Keeping away from triggers like outrageous cold and drying out is essential.
- Standard development with experts is fundamental.

Torment Emergency The executives Plan:
- Customized plans assist people with overseeing torment immediately.
- Created with medical services suppliers to further develop torment emergency results.[28]

Hereditary counciling:
- Prudent for people and families considering having youngsters.
- Gives data about the hereditary dangers and choices.

Regular Observing and adjustment:
- Treatment plans ought to be consistently inspected and changed.
- Close coordinated effort with a medical care group work in sickle cell sickliness is significant.
- Progressing Exploration and Clinical

Ongoing research and clinical trials:
- Propels in treatment choices are constantly developing.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

- Research offers expect further developed results and treatments later on future.[29]

Prevention

Secondary prevention strategies following sickle-cell disease focus on avoidance of sickle cell crisis or vaso-occlusive episodes; these include avoidance of dehydration, cold temperatures, or low oxygenation.

Preventive medicines help people with sickle cell disease stay well and avoid problems before they start. These medicines include hydroxyurea, crizanlizumab, voxelotor, and L-glutamine.

There are many effective ways to treat and prevent anaemia. Changes in diet can help reduce anaemia in some cases, including: eating foods that are rich in iron, folate, vitamin B12, vitamin A, and other nutrients. eating a healthy diet with a variety of foods.

Blood transfusion

Indication for Blood transfusion:

Blood transfusion are administered for a few ailments, including:

Anemia: At the point when an individual's red platelet count or hemoglobin levels are fundamentally low and can't be sufficiently made do with different medicines.

Surgery: To supplant blood lost during surgeries.

Trauma: For people who have lost a lot of blood because of mishaps or wounds.[30]

Disease Medicines: Some malignant growth medicines, similar to chemotherapy, can diminish the development of red platelets and platelets, requiring bondings.

Draining Problems: In instances of serious draining issues, like hemophilia, where the blood needs thickening elements.

Bone Marrow Issues: People with bone marrow problems or disappointment might expect bondings to keep up with solid platelet counts.[31]

Blood classifications and Similarity:

Before a blood bonding, the blood classification of both the contributor and the not set in stone to guarantee similarity. The ABO blood bunch framework and the Rh factor (positive or negative) are vital contemplations.[32]

Blood classifications:

A: Has An antigens on the outer layer of red platelets.

B: Has B antigens on the outer layer of red platelets.

AB: Has both An and B antigens.

O: Has no An or B antigens.

Rh Variable:

Positive (+): Presence of the Rh antigen.

Negative (-): Nonappearance of the Rh antigen.

Blood classification similarity is as per the following:

A can get An or O blood.

B can get B or O blood.

Stomach muscle can get A, B, Abdominal muscle, or O blood.

O can get O blood.

The Rh factor should likewise coordinate (+ can get + or - blood, while - can get - blood).[33]

Blood donation and Screening:

Blood for bonding is acquired from volunteer benefactors or through blood donation centers. Given blood goes through thorough screening and testing to guarantee it is protected and viable for bonding. Screening incorporates checks for irresistible sicknesses like HIV, hepatitis, and syphilis.

Blood components:

Blood can be isolated into its parts for bonding, contingent upon the patient's particular necessities:

Red blood cells (RBCs): Utilized essentially to treat frailty or to supplant lost blood during a medical procedure or injury.

Platelets: Significant for blood thickening, platelet bondings are given to people with draining problems or low platelet counts.

Plasma: Plasma contains coagulating factors and is utilized for people with draining problems or liver sickness.

Cryoprecipitate: Wealthy in thickening variables, it is utilized for people with specific draining problems or during monstrous bondings.

The transfusion process:

Patient Appraisal: The medical care group evaluates the patient's condition, decides the requirement for a bonding, and checks similarity.

Informed consent: informed assent is gotten from the patient or their legitimate gatekeeper in the wake of making sense of the dangers and advantages of the bonding.

Blood administration: The blood is directed through an intravenous (IV) line. The pace of

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1634-1642 www.ijprajournal.com ISSN: 2249-7781

implantation fluctuates relying upon the patient's condition.

Monitoring: Important bodily functions (pulse, circulatory strain, and temperature) are checked during the bonding to recognize any unfavorable responses.

Transfusion reaction management: In uncommon cases, a patient might encounter a bonding response, which can go from gentle to serious. Responses are quickly overseen by halting the bonding and giving suitable treatment.

Post-transfusion Care: After the bonding is finished, the patient is observed for any postponed responses.

Blood bondings are by and large safe when appropriately coordinated and managed. Nonetheless, they convey a few dangers, including bonding responses and the transmission of contaminations. Medical care suppliers follow severe conventions to limit these dangers and guarantee the prosperity of the patient getting the bonding.[34,35,36]

Future preparation.

Gene therapy and gene editing: Progresses in quality treatment and quality altering methods, for example, CRISPR-Cas9, offer the potential for a fix or long haul therapy for sickle cell iron deficiency by remedying the fundamental hereditary change.

Clinical preliminaries and examination studies are progressing to investigate these inventive methodologies-

Stem cell Transplantation: Bone marrow or immature microorganism transfers from viable givers might possibly fix sickle cell sickliness. Future endeavors might zero in on working on the accessibility and security of these techniques.

Investigation into haploidentical (half-coordinated) transfers and decreased power molding regimens is progressing to extend benefactor choices and diminish relocate related gambles.[37]

Disease modifying Treatments: Proceeded with research expects to recognize new illness changing medications and therapies that can additionally diminish the recurrence and seriousness of sickle cell emergencies.Designated treatments that address explicit parts of the illness, like aggravation and platelet grip, are being investigated.

Pain management related : Research endeavors are continuous to further develop torment the executives techniques, including the advancement of new agony drugs and intercessions.Customized torment the executives plans might turn out to be more custom-made to individual patient necessities.

Screening and Early Identification: Propels in infant screening methods and hereditary testing can prompt prior conclusion and mediation in babies with sickle cell illness.Early distinguishing proof considers convenient treatment and preventive measures.[38]

Telemedicine and Remote

Checking: Telemedicine and remote checking advances are probably going to turn out to be progressively significant for overseeing sickle cell iron deficiency, permitting patients to helpfully get to mind and discussions more.Remote checking can assist with following sickness movement and therapy reactions.

Patient Instruction and Self-

Administration: Future arrangements might incorporate improved patient instruction projects to enable people with sickle cell paleness to all the more likely deal with their condition and perceive the indications of entanglements.Steady assets and taking care of oneself instruments can work on personal satisfaction.

Medical services Framework and Access: Endeavors to further develop medical services framework and admittance to specific consideration for people with sickle cell iron deficiency are significant.This incorporates guaranteeing admittance to master medical services suppliers, clinical preliminaries, and extensive consideration habitats.

Promotion and Public awareness ness: Proceeded with promotion and public mindfulness missions can assist with raising subsidizing, backing, and comprehension of sickle cell sickliness.Advancing exploration and destigmatizing the condition are fundamental for progress.

Global Cooperation: Joint effort among analysts, medical care experts, and associations overall can speed up progress in the field of sickle cell pallor.Sharing information and assets can prompt more powerful medicines and worked on quiet results.[39,40]

II. CONCLUSION

Sickle cell is a complex hereditary problem that influences a great many individuals around the world. While there is no remedy for the condition, continuous examination, clinical progressions, and developing therapy systems offer expect further developed results and personal

satisfaction for people with sickle cell weakness.The administration of sickle cell iron deficiency includes a complex methodology, including infection changing drugs, torment the board, blood bondings, and preventive measures. Quality treatment and quality altering hold the potential for a fix, while undifferentiated cell transplantation offers a promising choice for certain patients.As we plan ahead, it is fundamental to underscore the significance of early identification, patient training, and impartial admittance to particular consideration.[41] Telemedicine, remote checking, and headways in medical services framework can improve the administration of sickle cell iron deficiency and furnish patients with more helpful admittance to mind.Backing, public mindfulness, and global coordinated effort are essential in driving exploration, subsidizing, and support for people living with sickle cell paleness. Together, we can make progress toward a future where further developed medicines and, at last, a fix are reachable, guaranteeing a superior personal satisfaction for those impacted by this difficult condition.[42]

REFERENCE

[1]. Embury SH, Hebbel RP, Mohandas N, Steinberg MH (ed). Sickle cell disease: basic principles and clinical practice. New York: Raven Press; 1994. p.599-621.

[2]. J. K. Onwubalili, “Sickle cell anaemia and reincarnation beliefs in Nigeria,” The Lancet, vol. 2, no. 8364, p. 1423, 1983.

[3]. E. Nzewi, “Malevolent ogbanje: recurrent reincarnation or sickle cell disease?” Social Science and Medicine, vol. 52, no. 9, pp. 1403–1416, 2001.

[4]. Platt OS, Brambilla DJ, Rosse WF; Mortality in Sickle Cell Disease. Life Expectancy and Risk Factors for Early Death. N. Engl J Med, 1994; 330 (23): 1639-1644.

[5]. Available:https://en.wikipedia.org/wiki/Red _blood_cell

[6]. Sickle Cell Disease Core Concepts for the Emergency Physician and Nurse Epidemiology, Genetics, Pathophysiology Spring Paula Tanabe, PhD, RN, FAEN; 2013.

[7]. Geller AK, O'Connor MK. The sickle cell crisis: A dilemma in pain relief. In Mayo Clinic Proceedings. Elsevier. 2008;83(3): 320-323.

[8]. Gardner RV. Sickle cell disease: Advances in treatment. Ochsner Journal. 2018;18(4): 377-389

[9]. KonothyAhulu FD; Effect of Environment on Sickle Cell Disease in West Africa; Epidemiological and Clinical Considerations, 2004.C.V. Mosby Co, St. Louis.

[10]. Desai DV, Hiren D; Sickle Cell Disease. History and Origin. The Internet Journal of Hematology, 2004; 1(2).

[11]. Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. American Journal of Obstetrics and Gynecology. 2008 Aug 1;199(2):125–e1. doi: 10.1016/j.ajog.2008.04.016. [PubMed] [CrossRef] [Google Scholar]

[12]. Hassell K. Pregnancy and sickle cell disease. Hematology/Oncology Clinics. 2005 Oct 1;19(5):903–16. doi: 10.1016/j.hoc.2005.07.003. [PubMed] [CrossRef] [Google Scholar]

[13]. Rahimy MC, Gangbo A, Adjou R, Dequenon C, Goussanou S, et al. Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting. Blood. 2000;96:1685–1689. [PubMed] [Google Scholar]

[14]. Rogers DT, Molokie R.Sickle cell disease in pregnancy. ObstetGynecol Clin North Am 2010;37(2):223–237. DOI: 10.1016/j.ogc.2010.02.015.

[15]. Gluckman P.D.et al. A conceptual framework for the developmental origins of health and disease. J. Dev. Orig. Health Dis. 2010; 1: 6-18.

[16]. Barres R. ZierathJ.R.The role of diet and exercise in the transgenerational epigenetic landscape of T2DM. Nat. Rev. Endocrinol. 2016; 12: 441-451

[17]. National Institute for Health and Clinical Excellence. Antenatal care. Routine care for the healthy pregnant woman. NICE clinical guideline 62. London: NICE; 2010 [www.nice.org.uk/CG062].

[18]. Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015; 125: 3316– 25.

[19]. Boafor TK, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y,

Segbefia C, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016; 123: 691– 8.

[20]. No GT. Management of sickle cell disease in pregnancy. London: Royal college of Obstetricians and Gynaecologists; 2011. Jul,

[21]. Neel, J. V. The inheritance of sickle cell anemia. Science 110, 64–66 (1949).

[22]. Steinberg, M. H. & Sebastiani, P. Genetic modifiers of sickle cell disease. Am. J. Hematol. 87, 795–803 (2012).

[23]. Platt, O. S. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639–1644 (1994). This landmark natural history study established life expectancy and risk factors for mortality for SCD in the United States.

[24]. Piel, F. B., Steinberg, M. H. & Rees, D. C. Sickle cell disease. N. Engl. J. Med. 376, 1561–1573 (2017).

[25]. Ware, R. E., de Montalembert, M., Tshilolo, L. & Abboud, M. R. Sickle cell disease. Lancet 390, 311–323 (2017).

[26]. Serjeant, G. R. & Serjeant, B. E. Management of sickle cell disease; lessons from the Jamaican Cohort Study. Blood Rev. 7, 137–145 (1993).

[27]. Bonds, D. R. Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev. 19, 99–110 (2005).

[28]. Quinn, C. T., Rogers, Z. R., McCavit, T. L. & Buchanan, G. R. Improved survival of children and adolescents with sickle cell disease. Blood 115, 3447–3452 (2010).

[29]. Gardner, K. et al. Survival in adults with sickle cell disease in a high-income setting. Blood 128, 1436–1438 (2016).

[30]. Grosse, S. D. et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am. J. Prev. Med. 41, S398–405 (2011).

[31]. Allison, A. C. Protection afforded by sickle-cell trait against subtertian malarial infection. BMJ 1, 290–294 (1954).

[32]. Luzzatto, L. Sickle cell anaemia and malaria. Mediterr. J. Hematol. Infect. Dis. 4, e2012065 (2012).

[33]. Piel, F. B. et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat. Commun. 1, 104 (2010).

[34]. Piel, F. B. et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 381, 142–151 (2013).

[35]. Weatherall, D. J. The importance of micromapping the gene frequencies for the common inherited disorders of haemoglobin. Br. J. Haematol. 149, 635–637 (2010).

[36]. Piel, F. B. et al. The distribution of haemoglobin C and its prevalence in newborns in Africa. Sci. Rep. 3, 1671 (2013).

[37]. Piel, F. B., Hay, S. I., Gupta, S., Weatherall, D. J. & Williams, T. N. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 10, e1001484 (2013). This study places the disease burden of SCA into a global perspective.

[38]. Diallo, D. A. & Guindo, A. Sickle cell disease in sub-Saharan Africa: stakes and strategies for control of the disease. Curr. Opin. Hematol. 21, 210–214 (2014).

[39]. Therrell, B. L. Jr., Lloyd-Puryear, M. A., Eckman, J. R. & Mann, M. Y. Newborn screening for sickle cell diseases in the United States: a review of data spanning 2 decades. Semin. Perinatol. 39, 238–251 (2015).

[40]. Charlton, M. NHS Sickle Cell and Thalassaemia Screening Programme Data Report 2015/16: Trends and Performance Analysis (Public Health England, 2017).

[41]. Benson, J. M. & Therrell, B. L. Jr. History and current status of newborn screening for hemoglobinopathies. Semin. Perinatol. 34, 134–144 (2010).

[42]. Feuchtbaum, L., Carter, J., Dowray, S., Currier, R. J. & Lorey, F. Birth prevalence of disorders detectable through newborn screening by race/ethnicity. Genet. Med. 14, 937–945 (2012).